{
    "nctId": "NCT02888704",
    "officialTitle": "Phase I Clinical Trial to Evaluate the Safety, Tolerance, and Exploratory Efficacy of ADSTEM Inj. in Patients With Moderate to Severe, Subacute and Chronic Atopic Dermatitis",
    "inclusionCriteria": "* Of either gender, aged \u226519 and \u226470 years\n* Atopic dermatitis subjects who are coincident with Hanifin and Rajka diagnosis criteria\n* Subacute and chronic atopic subjects who have atopic dermatitis symptoms continually at least 6 months\n* Subjects with over moderate atopic dermatitis (SCORAD score \\> 20)\n* Subjects who understand and voluntarily sign an informed consent form\n* Must have minimum age of 19 Years\n* Must have maximum age of 70 Years",
    "exclusionCriteria": "* Subjects who have systemic infection\n* Subjects who have human Immunodeficiency virus (HIV), hepatitis B virus (HBV), and hepatitis C virus (HCV)\n* Subjects who need to take the medicine which is prohibited during this study\n* Subjects who have asthma\n* Subjects who can not stop treatment with topical steroids (group 1\\~5), oral antibiotics, whole body photochemotherapy, immunosuppressive drug within 4 weeks before the treatment visit\n* Pregnant, breast-feeding women or women who plan to become pregnant during this study (Females of childbearing potential must have a negative urine pregnancy test)\n* Subjects who currently participate in other clinical trial or participated in other clinical trial within 30 days\n* Subjects who had a serious adverse events during stem cell therapy\n* Subjects who had a hypersensitivity to antibiotics or antimycotics\n* Subjects who creatinine value is more than two times of the upper limit of the normal range at screening test\n* Subjects who aspartate transaminase/alkaline transaminase (AST/ALT) value is more than three times of the upper limit of the normal range at screening test\n* Subjects who have any other condition which the investigator judges would make patients unsuitable for study participation"
}